

---

Assisting the clinical development program of  
**Oncology Treatment**  
**Coming Off-Patent**  
in next few years


We are now supporting you through all the stages in a drug development continuum

---





# An overview of Oncology Drugs (Small Molecules) that are going off-patent in next 8 years



## Are you also eyeing them?


Oncology Drug	Therapeutic Indication	Year of Patent Expiry
PALBOCICLIB	Breast Cancer	2023
PAZOPANIB	Renal Cell Carcinoma	2023
LENALIDOMIDE	Multiple Myeloma	2024
NILOTINIB	Chronic Myelogenous Leukemia	2024
EVORLIMUS	Pancreatic Cancer	2025
PROMALIDOMIDE	Multiple Myeloma	2025
IBRUTINIB	Chronic Lymphocytic Leukaemia	2026
BENDAMUSTINE	Chronic Lymphocytic Leukaemia	2026
ABIRATERONE ACETATE	Prostate Cancer	2027
NIVOLUMAB	Non- small cell lung cancer	2028
ABEMACICLIB	Breast Cancer	2029
ALECTINIB	Non-small cell lung cancer	2030

One stop destination for clinical trial design, site selection, execution, bioanalysis, and regulatory guidance services for Oncology drugs



# Integrate Veeda Clinical Research's Scientific Capabilities In Your Next Oncology Study

- Study Design and Execution
- Project Management
- Volunteer recruitment
- Conducting Feasibility & Site Set up activity
- Site Monitoring and Safety Monitoring
- Clinical Pharmacology Services
  - Medical Writing
  - Investigator Brochures
  - Clinical Trial Protocol
  - Informed Consent Forms
  - Clinical Study Reports (CSRs)
- Biostatistics & Clinical Data Management
- Bioanalytical services
- Safety Database and Pharmacovigilance
- Regulatory Guidance



## We Deliver Fast and Reliable Clinical Trial Experience (Phase I & Phase II) For Oncology Drugs

Study title	TherapyArea
A Phase II Study in Non-Small Cell Lung Cancer-	Oncology
A Phase I Followed by a Randomized, Phase II Study in Small Cell Lung Cancer (SCLC)	Oncology
Phase II clinical study in non-small cell lung cancer and colorectal cancer	Oncology
Phase 2b Study in Advanced Non-Small Cell Lung Cancer	Oncology
Phase II study of Inhibitor of PD-L1, PD-L2, and VISTA pathways in Different tumor types (5 cohorts)	Oncology



# Our Experience in Patient Based Pk Endpoint Studies for Different Oncology Drugs

ONCOLOGY DRUGS	INDICATION	STATUS
Etoposide	Small Cell Lung Cancer	Completed
Imatinib	Chronic Myeloid Leukemia	Completed
Capecitabine	Metastatic Breast Cancer & Colorectal Cancer	Completed
Everolimus, Etoposide, Leuprolide	Renal Cell Carcinoma	Completed
Liposomal Doxorubicin Injectable IV Infusion, Doxorubicin Hcl (Pegylated Liposomal)	Ovarian and Metastatic Breast Cancer	Completed
Paclitaxel, Capecitabine	Metastatic Breast Cancer	Completed
Bortezomib	Multiple Myeloma	Completed
Liposomal Doxorubicin, Paclitaxel	Breast Cancer	Ongoing
Leuprolide	Advance Prostate Cancer	Ongoing
Doxorubicin	Ovarian Cancer	Ongoing

## New methods for oncology drugs can be validated and developed in 4 weeks















# More than 40 Readily Available Validated Bioanalytical Methods for Oncology Drugs (Small Molecules)

METHODS AVAILABLE FOR DRUGS	INDICATION
5-Azacitidine	Acute Myeloid Leukemia
Docetaxel (Free), Afatinib, Docetaxel (Total), Erlotinib, Gefitinib, Nintedanib, Osimertinib, Pemetrexed, Trametinib	Non-small Cell Lung Cancer
Doxorubicin Metabolite (Doxorubicinol), Doxorubicin (Free), Doxorubicin (Liposomal), and Doxorubicin (Total)	Multiple Indication: Certain Types of Bladders, Breast, Lung, Stomach, Ovarian, and White Blood Cell Cancers
Paclitaxel (Free, Unbound)	Multiple Indication: Breast, Ovarian, and Non-small Cell Lung Cancer
Abiraterone	Metastatic Prostate Cancer
Axitinib, Pazopanib, Sorafenib, Sunitinib	Renal Cell Carcinoma
Bexarotene, Binimetinib	Skin Cancer
Bortezomib	Multiple Myeloma
Bosutinib, Dasatinib, Nilotinib	Chronic Myeloid Leukemia
Cabozantinib, Lenvatinib	Thyroid Cancer
Enzalutamide	Prostate Cancer
Etoposide	Small Cell Lung Cancer
Anastrozole, Fluvestrant, Lapatinib, Letrozole, Palbociclib	Breast Cancer
Hydroxycarbamide (Hydroxyurea)	Multiple indication: CML, Ovarian, Head and Neck Carcinomas
Ibrutinib	Chronic Lymphocytic Leukaemia
Imatinib	Leukemia
Leuprolide	Prostate Cancer
Methotrexate	Multiple indication: Breast, Lung, Head and Neck Carcinomas, Leukemias
Olaparib	Ovarian Cancer
Pomalidomide	Multiple Myeloma
Temozolomide	Brain Cancer
Ubenimex	Multiple indication: Myelonus leukemia, lung cancer, and Nasopharyngeal cancer



# Strong Bioanalytical Capabilities to keep your study on track

- |  |   |   |   |
|--|---|---|---|
|    | Method development and validation for a wide spectrum of drug substances                                      |    | State of art Bio analytical Lab equipped with high end sensitive equipment's to achieve the required LLOQ                                     |
|    | Chiral Molecule Analysis  |    | 100% data review by Bio-analytical Quality Monitors   |
|    | Hormones and vitamin analysis   |    | Capability to develop methods with lowest quantification level- up to 0.1 pg  |
|   | Optimized acceptable methodology for endogenous moieties, unstable drug & metabolite(s) and chiral separation |   | Average processing capacity of 1,00,000 samples per month   |
|  | Trained Bio analysts to handle complex sample processing  |  | More than 1066 available Bioanalytical Methods for NCEs, Generics, Complex Generics, Large Molecule Assays, & Pharmacodynamics/Immunogenicity |

## We Are Committed to our Patient's Safety and their Wellbeing

- **Experienced and Qualified Safety Team**
  - Qualified, educated, and trained study staff
  - ACLS, BLS trained Investigators, Clinical Research physician and Nursing staff
  - Designated Resuscitation officer
  - BLS trained Phlebotomist, Clinical custodian, security and Clinical Quality Monitor team
- **Medical monitors prepare study specific Risk mitigation strategy documents, in order to define the molecule specific risks and measures to mitigate them**
- **Medical monitors also prepare Safety management plan which helps in identification of any safety concerns developing in the subject and how to report them to the relevant stake holders in a timely manner**
- **Medical monitor and CRAs review blinded patient safety data so that safety issues are identified early and managed appropriately**
- **Well-equipped and maintained special care area – to handle medical emergency**
- **Provisions of cardiac monitor, defibrillator, ECG machine, suction machine, oxygen cylinder and handy kits like Cardiac Arrest Kit and Anaphylaxis Kit.**



---

## What makes Veeda Clinical Research a perfect choice for your next Oncology Trial?

- Extensive Scientific Competence to service a diverse client base
- High Customer Centricity and Satisfaction
- Skilled personnel with focus on Continuous Professional Development
- Robust Quality & Regulatory Compliance
- State of the Art Infrastructure for handling complex studies
- Veeda Group has an Investigator Database of 150 Oncologists and has worked at 90 sites across India
- Experience in executing studies pertaining to different dosage forms (solid, semisolid, suspension, injectable, inhalation, and topical drugs)
- Diverse volunteer database (More than 64,859)
- Providing full service as well as functional services in all the stages of drug discovery and development to support critical drug development programs of global (Bio) Pharmaceutical companies

To know more about  
our expertise in Oncology Clinical Trials, mail us at  
[info@veedacr.com](mailto:info@veedacr.com)

---

Partners in creating a healthier tomorrow

---

 +91 79 6777 3000

 [www.veedacr.com](http://www.veedacr.com)